Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

( views:444, downloads:0 )
Author:
GAN Qiao-rong(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
PAN Chen(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
ZHOU Rui(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
LIN Ming-hua(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
CHEN Li(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
LIN Chun(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
LIN Cai-wen(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
LI Qin(Department of Liver Diseases, the Affiliated Infectious Diseases Hospital of Fujian Medical University, Fuzhou 350025, China)
HUANG Jian-rong()
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
Volume 05, Issue 04, 2012
DOI:
10.3760/cma.j.issn.1674-2397.2012.04.008
Key Word:
Hepatitis B; Liver failure; Antiviral agents; Artificial liver support system

Abstract: Objective To investigate the optimal therapy for patients with acute-on-chronic liver failure induced by hepatitis B.Methods A total of 302 patients with acute-on-chronic liver failure induced by hepatitis B in the Affiliated Infectious Diseases Hospital of Fujian Medical University were enrolled during January 2008 to January 2010.Patients were divided into group A ( medical treatment,n =57 ),group B (medical + antiviral treatment,n =80),group C ( medical + antiviral + artificial liver support system (ALSS),n =124) and group D (medical + antiviral + ALSS + traditional Chinese medicine treatment,n =41 ).Liver and renal function,prothrombin activity (PTA) and HBV DNA load were observed at the baseline,week 1,4,8,12 and the end of the treatment.All groups were followed up for 48 weeks to observe the survival rates.Kruskal-Willis H test was used to compare the efficacies in four groups,and Cox proportional hazards regression model was used for survival analysis. Results There was no difference among four groups in curative effects at week 4 ( H =3.213,P =0.360 ),but there was significant difference at week 12 (H =8.722,P =0.033).The one-year mortality rates for groups A,B,C,D were 36.84% (21/57),32.50% (26/80),26.61% (33/124) and 24.39% ( 10/41 ),respectively.The death risks of group C and D were 0.566 and 0.396 times of that in group B ( P =0.036 and 0.016).Conclusion Nucleoside analogue and ALSS plus medical treatment can effectively increase the survival rates of the patients with acute-on-chronic liver failure induced by hepatitis B.

  • [1]Chuang CS,Tung SY,Lee IL,et al. Clinical features and outcome of chronic viral hepatitis with acute exacerbation in patients with concurrent infections of hepatitis B and C virus.Dig Dis Sci,2008,53(2):511-516.
  • [2]Wang YM,Tang YZ. Antiviral therapy for hepatitis B virus associated hepatic failure.Hepatobiliary Pancreat Dis Int,2009,8(1):17-24.
  • [3]Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant,2005,19 (3):321-326.
  • [4]Kjaergard LL,Liu J,Ms-Nielsen B,et al.Artificial and bioartificial support systems for acute and acute-on-chronic liver failure:a systematic review.JAMA,2003,289 (2):217-222.
  • [5]Polson J,Lee WM.American Association for the Study of Liver Disease.AASLD position paper:the management of acute liver failure.Hepatology,2005,41 (5):1179-1197.
  • [6]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝组学.肝衰竭诊疗指南.中华肝脏病杂志,2006,14(9):643-646.
  • [7]Tsang SW,Chan HL,Leung NW,et al.Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection.Aliment Pharmacol Ther,2001,15 (11):1737-1744.
  • [8]袁静,周伯平,胡毅文.拉米夫定治疗慢性重型乙型肝炎疗效观察.中华传染病杂志,2002,12(19):372-373.
  • [9]林炳亮,谢冬英,张晓红,等.恩替卡韦治疗慢加急性乙型肝炎肝衰竭的疗效和预测因素研究.中华临床感染病杂志,2011,4(1):21-24.
  • [10]骆抗先,乙型肝炎基础和临床.北京:人民卫生出版社,2006,55-57.
  • [11]叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.中华肝脏病杂志,2009,17(8):638-640.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn